| Home | E-Submission | Sitemap | Contact Us |  
Korean J Med > Volume 87(1); 2014 > Article
The Korean Journal of Medicine 2014;87(1): 19-25.
Peroxisome Proliferator-Activated Receptor (PPAR) α/γ 작용제
대구가톨릭대학교 의과대학 내과학교실
Peroxisome Proliferator-Activated Receptor (PPAR) α/γ Agonist
Jihyun Lee
Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea
Corresponding Author: Jihyun Lee ,Tel: +82-53-650-4051, Fax: +82-53-651-4009, Email: jhlee9@cu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Peroxisome proliferator-activated receptor (PPAR) agonists improve glucose control and insulin sensitivity, reduce concentrations of atherogenic lipoproteins, and decrease circulating levels of inflammatory mediators. PPAR activation is considered an important pharmacologic target for patients with type 2 diabetes. However, the PPAR agonists in clinical use have undesirable side effects, including weight gain, heart failure, and bone fractures. PPAR α/γ dual agonists each target one or more of the key cardiometabolic risk factors of diabetic dyslipidemia, insulin resistance, hyperglycemia, and inflammation; thus, combining their benefits to provide glucose control and ameliorate cardiovascular risks has emerged as an attractive treatment option. Aleglitazar, which was designed to balance the activation of PPAR α/γ, proved efficacious in improving glycemic control and lipid homeostasis and is anticipated to minimize PPAR-related side effects. Whether the effects of aleglitazar on cardiometabolic risk factors translate into improved cardiovascular outcomes, particularly in high-risk patients, is currently being evaluated by AleCardio, a large, long-term, time-, and event-driven outcome study of type 2 diabetics with recent acute coronary syndrome.
Keywords: PPAR α/γ agonist; Diabetic dyslipidemia; Insulin resistance; Aleglitazar
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community